Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 3Mucositis 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Febrile Neutropenia 2Polycystic Ovary Syndrome 1Neurotoxicity Syndromes 1Neoplasms, Plasma Cell 1Lymphoma, Non-Hodgkin 1Inflammation 1Hematologic Neoplasms 1Early Stage Triple Negative ER Low Breast Cancer 1Disease Progression 1Cytokine Release Syndrome 1Colorectal Neoplasms 1Burkitt Lymphoma 1Arthritis, Rheumatoid 1

Interventions

siltuximab 3tocilizumab 1talquetamab 1obinutuzumab 1glofitamab 1axicabtagene ciloleucel 1Oxaliplatin 1Interleukin 1 Receptor Antagonist Protein 1Gemcitabine 1Gelsolin 1Dexamethasone 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Cytokine Release Syndrome × Interleukin 1 Receptor Antagonist Protein × Clear all
NCT04150913 2025-11-25

A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

Massachusetts General Hospital

Phase 2 Completed
15 enrolled 17 charts
Lymphoid

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡